Results 41 to 50 of about 4,657 (129)

Lecanemab and Donanemab in Early Alzheimer’s Disease: A Systematic Review of Clinical, Biomarker, and Safety Outcomes

CHRISMED Journal of Health and Research
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia worldwide. Characterized by amyloid-beta (Aβ) accumulation, tau pathology, and cognitive decline, it has long lacked effective disease-modifying ...
Dharmendra Kumar Gupta, Arunima Chaudhuri   +1 more
doaj   +1 more source

The value of timely treatment with anti‐amyloid therapy for Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract INTRODUCTION Anti‐amyloid therapies can slow Alzheimer's disease (AD) progression; diagnostic and treatment delays might reduce their value. METHODS Using dynamic microsimulation, we estimated the gross societal value of anti‐amyloid treatment for Americans with early symptomatic AD. A treatment scenario slowed the rate of clinical progression
Jack M. Chapel, Bryan Tysinger, Hossein Pourmand, Dana Goldman, Paul Aisen, for the Alzheimer's Disease Neuroimaging Initiative   +5 more
wiley   +1 more source

Sex differences in treatment effects of lecanemab and donanemab: A Bayesian reanalysis of CLARITY‐AD and TRAILBLAZER‐ALZ2

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION This study investigated evidence for or against a difference in treatment effect between women and men for lecanemab and donanemab. METHODS Data were derived from supplementary analyses of the regulatory studies CLARITY‐AD (lecanemab) and ...
Stefan J. Teipel, Yi Tang, Ara Khachaturian   +2 more
doaj   +1 more source

Lecanemab for mild Alzheimer disease – is there a way forward?

Drugs in Context
This Editorial reviews data on the efficacy and adverse effects of lecanemab amongst individuals with mild Alzheimer disease. Additionally, the recent controversy regarding the rejection by the EMA of a marketing authorization request for lecanemab ...
Rajesh R Tampi
doaj   +1 more source

Genetic evidence supports a cortical neuroprotective role of GLP‐1 receptor activation in Alzheimer's disease: A drug‐target Mendelian randomization study

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract INTRODUCTION Whether glucagon‐like peptide‐1 (GLP‐1) receptor (GLP‐1R) activation lowers Alzheimer's disease (AD) risk via peripheral metabolic improvement or direct neuroprotection remains unclear. METHODS Using blood and brain‐cortex cis‐acting expression quantitative trait loci (cis‐eQTLs) for GLP‐1R as instruments, we performed cis ...
Li Jiang, Xinyuan Chen, Jiangshun Qian, Kaiwen Fang, Chenyuan Dai, Dong Chang, Liang Jin, Wenjin Huang, Yuzheng Wang, Xiaomei Duan, Juan Wan, Mingqiang Li, Wendiao Zhang, Jinchen Li, Zijian Xiao, Heng Wu, Qingtuan Meng, Beisha Tang   +17 more
wiley   +1 more source

Long‐term value of lecanemab to individuals and families

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION An assessment of the value of lecanemab for patients living with Alzheimer's disease (AD) and their care partners provides them and their health‐care providers important information for deciding treatment initiation.
Bryan Tysinger, Yifan Wei, Hanke Heun‐Johnson, Julie M. Zissimopoulos   +3 more
doaj   +1 more source

miR‐214‐3p and NCKAP1: A microglial functional dimension of Alzheimer's progression

Alzheimer's &Dementia, Volume 22, Issue 10, October 2026.
Abstract INTRODUCTION Biological Alzheimer's disease (AD) pathology does not fully explain the marked heterogeneity in clinical severity or progression. We investigated whether patient‐derived induced microglia‐like cell (iMG) profiles capture a functional dimension of AD progression beyond conventional plasma biomarkers.
Min‐Young Noh, Yeonsil Moon, Sungwoo Kang, Won‐Jin Moon, Hee‐Jin Kim, Sang Won Seo, Sugyeong Ahn, Mi‐Hyeon Kang, Yong Sung Kim, Hyunkee Kim, Jae‐sung Bae, Hee Kyung Jin, Hojin Choi, Seong‐Ho Koh, Kee Hyung Park, Gregory S. Day, Guojun Bu, Seung Hyun Kim   +17 more
wiley   +1 more source

Reply to “CSF Amyloid‐β Risk Stratification in CAA: A Missing Link for Anti‐Amyloid Therapy Safety”

Annals of Neurology, Volume 100, Issue 5, Page 1118-1119, November 2026.
Philipp Arndt, Stefanie Schreiber
wiley   +1 more source

Investigating patient eligibility for anti-amyloid monoclonal antibody treatment of Alzheimer's disease: real-world data from an Austrian psychiatric memory clinic population

BJPsych Open
Background Pharmacological treatment options for patients with dementia owing to Alzheimer's disease are limited to symptomatic therapy. Recently, the US Food and Drug Administration approved the monoclonal antibody lecanemab for the treatment of amyloid-
Michaela Defrancesco, Elke R. Gizewski, Stephanie Mangesius, Malik Galijasevic, Irene Virgolini, Alexander Kroiss, Josef Marksteiner, Juliane Jehle, Burak Doganyigit, Alex Hofer   +9 more
doaj   +1 more source

Alzheimer's Disease Beyond Amyloid: Lessons From Atherosclerosis

Annals of Clinical and Translational Neurology, Volume 13, Issue 10, Page 2175-2183, October 2026.
Marcello Ciaccio, Luisa Agnello
wiley   +1 more source